Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 29;2(11):e00198.
doi: 10.1016/j.heliyon.2016.e00198. eCollection 2016 Nov.

The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination

Hans-Christian Slotved  1 , Tine Dalby  1 , Zitta Barrella Harboe  2 , Palle Valentiner-Branth  3 , Victoria Fernandez de Casadevante  3 , Laura Espenhain  3 , Kurt Fuursted  1 , Helle Bossen Konradsen  1
Affiliations

The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination

Hans-Christian Slotved et al. Heliyon. .

Abstract

Since 2010, Denmark has included the 13-valent pneumococcal conjugated vaccine (PCV-13) in the childhood immunization programme. However, serotype 3 remains as an important cause of invasive pneumococcal disease (IPD) in Denmark. IPD surveillance data (1999-2016) was used to calculate the incidence and age-distribution of serotype 3 IPD, and the effect of PCV-13 on serotype 3 IPD incidence was examined. The incidence of serotype 3 IPD in the age group below 65 years was 0.51/100,000 pre PCV-13, and 0.45/100,000 post PCV-13. In the group 0-4 years, serotype 3 IPD incidence was 0.28/100,000 pre PCV-13, and 0.16/100,000 post PCV-13. Serotype 3 IPD incidence in the elderly showed a mean of 4.27/100,000 pre PCV-13, and 4.32/100,000 post PCV-13. PCV-13 childhood immunization in Denmark has not lead to a reduction of the incidence of IPD caused by serotype 3. The reason behind this missing effect needs to be investigated further.

Keywords: Immunology; Infectious diseases; Medicine.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The IPD incidence with the corresponding 95% CI indicated as error bars for serotype 3 in all three age groups from 1999 until 2016. Blue bars represent 0–4 years, green bars represent 5–64 years and red bars represent 65+ years. The curve represents the total incidence per year. The 2016 data is corrected for seasonal variation (IPD/60.6)*100.
See this image and copyright information in PMC

References

    1. Murray J., Agócs M., Serhan F., Singh S., Deloria-Knoll M., O'Brien K. Centers for Disease Control and Prevention (CDC). Global invasive bacterial vaccine-preventable diseases surveillance--2008-2014. MMWR Morb. Mortal. Wkly. Rep. 2014;63:1159–1162. - PMC - PubMed
    1. Harboe Z.B., Dalby T., Weinberger D.M., Benfield T., Mølbak K., Slotved H.C. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin. Infect. Dis. 2014;59:1066–1073. - PubMed
    1. Waight P.A., Andrews N.J., Ladhani S.N., Sheppard C.L., Slack M.P., Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect. Dis. 2015;15:535–543. - PubMed
    1. Rashid H., Khandaker G., Booy R. Vaccination and herd immunity: what more do we know? Curr. Opin. Infect. Dis. 2012;25:243–249. - PubMed
    1. Simell B., Auranen K., Käyhty H., Goldblatt D., Dagan R., O'Brien K.L. Pneumococcal Carriage Group: The fundamental link between pneumococcal carriage and disease. Expert. Rev. Vaccines. 2012;11:841–855. Review. - PubMed

LinkOut - more resources